Collectively, MAPK can lead to ICI resistance through many discovered pathways: through decreasing T lymphocyte activity via IL-6 and IL-10; by increasing expression of PD-L1 on tumor cells; and by promoting the co-expression of several ICs in T lymphocytes. The gene discussed is IL10; the disease is neoplasm.